A rare, progressive neurodegenerative disease associated with loss of macular photoreceptors in the retinas, MacTel type 2 ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due ...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly ...

Diagnos Inc. (“ DIAGNOS ” or the “ Corporation ”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

Neurotech Pharmaceuticals’ gene therapy comes in a surgical implant, and it’s now the first FDA-approved treatment for a rare vision-loss disorder. The approval handed out on March 5 covers ...

President Trump’s pick to lead the US Food and Drug Administration tells senators he will follow science and common sense ...

Inspira™ Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company") (Nasdaq: IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring ...

Perfuze, a medtech has raised €22m. With the infusion, the company will release its catheters to select stroke centres in the US.

"Now with an FDA-approved treatment ... allowing them the opportunity to preserve more functional vision over time." According to the prescribing information, common adverse events in the studies ...